Akoya Biosciences (AKYA) Scheduled to Post Quarterly Earnings on Thursday

Akoya Biosciences (NASDAQ:AKYA) is scheduled to issue its quarterly earnings data after the market closes on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Akoya Biosciences (NASDAQ:AKYA) last released its quarterly earnings data on Monday, August 5th. The company reported ($0.27) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.27). The company had revenue of $23.16 million during the quarter, compared to analyst estimates of $23.61 million. Akoya Biosciences had a negative net margin of 64.74% and a negative return on equity of 126.38%. During the same period in the prior year, the firm earned ($0.51) earnings per share. On average, analysts expect Akoya Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Akoya Biosciences Trading Up 4.9 %

NASDAQ AKYA opened at $3.24 on Thursday. Akoya Biosciences has a one year low of $1.88 and a one year high of $6.31. The company has a debt-to-equity ratio of 3.43, a quick ratio of 1.98 and a current ratio of 2.73. The company has a market capitalization of $160.38 million, a price-to-earnings ratio of -2.63 and a beta of 1.34. The company’s 50-day simple moving average is $2.81 and its two-hundred day simple moving average is $2.67.

Analysts Set New Price Targets

AKYA has been the subject of a number of recent research reports. Piper Sandler reduced their price objective on shares of Akoya Biosciences from $6.00 to $4.00 and set an “overweight” rating for the company in a research note on Tuesday, August 13th. JPMorgan Chase & Co. cut Akoya Biosciences from an “overweight” rating to a “neutral” rating in a research note on Tuesday, August 6th. Morgan Stanley downgraded Akoya Biosciences from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $4.00 to $3.00 in a research report on Tuesday, August 6th. Craig Hallum reduced their target price on shares of Akoya Biosciences from $7.50 to $7.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. Finally, BTIG Research cut shares of Akoya Biosciences from a “buy” rating to a “neutral” rating in a report on Tuesday, August 6th. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Akoya Biosciences has an average rating of “Moderate Buy” and an average price target of $6.56.

Akoya Biosciences Company Profile

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.